Our History

Launched Krestin (Poly-saccharide-K) in Japan to treat gastrointestinal, lung and breast cancer

Launched the first natural-type interferon beta preparations for brain tumour and skin cancer in Japan

Received approval of irinotecan, the first chemotherapy to demonstrate survival benefits in colorectal cancer

Launched denosumab in Japan for treatment of bone complications of multiple myeloma and bone metastases of solid tumours

>20 compounds in development directed at a range of diseases with unmet medical needs, with a focus on ADC technology

In January 2021, trastuzumab deruxtecan received EMA approval for HER2-positive metastatic breast cancer in the EU*

We have more than 40 years of experience in cancer treatment, innovations and research!


*Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens SmPC at www.ema.europa.eu

back to top

User login

Enter your username and password here in order to log in on the website